Glucagon-like peptide 1 receptor (GLP-1R) is present not only in the central nervous system and gastrointestinal tract but also in the pancreas, kidney, lungs, cardiomyocytes, vascular smooth muscle cells, and endothelium [25,26,27,28,29]
The cumulative, sustained-release mechanism means gaps in dosing can reduce effectiveness
Properly manufactured and reconstituted peptides remain completely clear and colourless throughout their 28-day refrigerated shelf life
GLP-1s: Changing the Obesity Treatment Narrative The seismic shift in obesity treatment, propelled by these medications like Wegovy (Semaglutide) and Zepbound (Tirzepatide), has opened up new possibilities